Bal Pharma Limited (BALPHARMA)

Loading page…

Bal Pharma Limited (BALPHARMA) · mywealthgrid

About

Bal Pharma Limited operates in pharmaceuticals with ₹135 Cr market cap and approximately ₹85 Cr quarterly revenue. Promoter-led at 50.86% stake alongside 48.99% public shareholding. Specific therapeutic segments and geographic presence require verification from investor filings.

Face value: ₹10

Market cap

₹168 Cr

P/E

23.4×

P/B

2.0×

Dividend yield

2.3%

ROE

7.9%

ROCE

18.8%

Debt / equity

1.94

OPM

10.2%

EPS (TTM)

₹4.5

Book value

₹51.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Profit volatility ₹3.7 Cr (Mar 2026) to ₹1.16 Cr (Jun 2026) undermines earnings predictability; operating margins compressed 350 bps in single quarter
Leverage D/E 1.94 against volatile earnings limits financial flexibility and refinancing optionality; verify debt maturity and covenant headroom
Revenue flat ₹73–88 Cr quarterly with no evident growth catalysts; verify competitive position, product pipeline, and pricing sustainability
Thin 9-12.65% OPM vulnerable to input cost inflation; verify hedging programs and cost pass-through capability

Generated analysis · source review pending

Growth drivers

Margin recovery: OPM peaked 12.65% (Mar 2026) vs 9% (Jun 2026); return to recent high would improve profits ~40% on stable ₹85 Cr quarterly revenue
Revenue scaling: ₹73–88 Cr quarterly baseline; growth hinges on product pipeline, therapeutic focus, and distribution reach — verify management plans
Capital efficiency: ROE 7.87% reflects limited value per capital deployed; improvement requires margin stabilization or faster asset turnover — verify capex and R&D allocation

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹105.6-5.8%1Y

Quick read

rule-based

Pros

+Dividend payout of 53% of profit

Cons

−Low return on equity of 9.6% (3-yr avg)
−Modest revenue growth of 4.5% a year over the last 5 years
−Heavily leveraged (debt/equity 1.9)
−Weak interest coverage of 1.4×

Research score

Structured signal from quality, growth, valuation and momentum.

54/100

Business quality: 16
Growth: 76
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	171	251	281	304	339	303	312
COGS	84	151	168	173	192	158	158
Gross profit	87	100	114	131	147	145	154
	82	75	90	106	116	116	122
	5	24	23	25	32	30	32
OPM %	2.8%	9.8%	8.4%	8.3%	9.3%	9.7%	10.2%
Depreciation	8	10	9	9	10	10	11
Interest	12	12	10	12	15	17	17
	2	1	5	1	3	2	2
Profit before tax	-14	4	9	5	9	5	6
Tax	-1	-1	3	2	2	-2	-0
Tax %	-4.7%	-14.9%	37.9%	44.8%	17.7%	-41.1%	-6.6%
	-13	5	6	3	7	7	6
PAT margin %	-7.5%	1.9%	2%	0.9%	2.2%	2.4%	2%
EPS (₹)	-8.6	3.3	3.8	1.7	4.9	4.6	4
EPS adjusted (₹)	-9.1	3.2	3.8	1.7	4.7	4.5	3.9
	—	29.9%	26.4%	59.9%	24.3%	26.3%	30.4%
Annual report	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	14	15	15	16	16	16	16
Reserves	—	39	44	48	53	62	66
Minority interest	—	—	—	—	—	—	0
	—	105	98	131	140	150	160
	—	82	104	118	111	108	134
Total equity & liabilities	—	240	261	313	320	336	376
	67	69	67	76	77	87	94
CWIP	—	0	2	0	0	3	7
Investments	—	0	0	0	7	2	2
	—	171	192	237	236	244	272
Total assets	—	240	261	313	320	336	376

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.8%	39.7%	40.4%	43.2%	43.5%

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	51.61%	51.23%	51.23%	51.23%	50.86%	50.86%	50.86%	50.86%	50.86%	50.86%	50.86%	50.86%
	0.14%	0.13%	0.13%	0.13%	0.13%	0.14%	0.14%	0.15%	0.22%	0.14%	0.14%	0.15%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	48.25%	48.64%	48.64%	48.64%	49.01%	49%	49%	48.99%	48.92%	49%	49%	48.99%
No. of shareholders	—	—	—	—	—	—	—	—	15,774	15,520	15,214	14,974

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Bal Pharma Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

16

Final dividend17 Sept 2026 · ex-date₹1.2
Dividend dividend18 Sept 2025 · ex-date₹1.2
Final dividend17 Sept 2024 · ex-date₹1.2
Final dividend18 Sept 2023 · ex-date₹1
Final dividend13 Sept 2022 · ex-date₹1
Final dividend16 Sept 2021 · ex-date₹1
Final dividend17 Sept 2019 · ex-date₹1
Dividend dividend14 Sept 2018 · ex-date₹1
Dividend dividend14 Sept 2017 · ex-date₹1
Dividend dividend15 Sept 2016 · ex-date₹1
Dividend dividend15 Sept 2015 · ex-date₹1
Dividend dividend12 Sept 2014 · ex-date₹1
Dividend dividend12 Sept 2013 · ex-date₹0.75
Dividend dividend17 Sept 2009 · ex-date₹0.75
Dividend dividend9 Sept 2008 · ex-date₹1
Dividend dividend7 Sept 2007 · ex-date₹0.75

1

Board meeting to consider results12 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

15 announcementsExport CSV

10 Sept 2026, 6:09 pmCompany Update

Clarification Regarding Movement In Price

General PDF

10 Sept 2026, 5:41 pmCompany Update

Clarification sought from Bal Pharma Ltd

Clarification

7 Sept 2026, 6:16 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment

Allotment of Equity Shares PDF

27 Aug 2026, 2:29 pmCorp. Action

Bal Pharma Ltd - 524824 - Intimation Of Record Date For Final Dividend

Record Date PDF

26 Aug 2026, 5:48 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

26 Aug 2026, 5:35 pmAGM/EGM

Bal Pharma Limited - Notice Of AGM

AGM PDF

26 Aug 2026, 5:20 pmAGM/EGM

Intimation - 39Th AGM Scheduled On 24Th September 2026

AGM PDF

25 Aug 2026, 10:57 amCompany Update

Clarification With Respect To Tentative Timeline For Utilization Of Net Proceeds Of Preferential Issue

General PDF

Date	Category	Subject	Filing
10 Sept 2026, 6:09 pm	Company Update General	Clarification Regarding Movement In Price	PDF
10 Sept 2026, 5:41 pm	Company Update Clarification	Clarification sought from Bal Pharma Ltd

Loading announcements…

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.8%	39.7%	40.4%	43.2%	43.5%

41 deals · 5 Aug 2021 – 21 Jul 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
21 Jul 2026	ORION STOCKS LTD	Bulk	NSE	Sell	1,22,544	₹89.70	₹1.10 Cr
21 Jul 2026	ORION STOCKS LTD	Bulk	BSE	Buy	1,20,073	₹89.58	₹1.08 Cr
21 Jul 2026	ORION STOCKS LTD	Bulk	NSE	Buy	16,325	₹89.69	₹0.15 Cr
21 Jul 2026	ORION STOCKS LTD	Bulk	BSE	Sell	8,104	₹89.80	₹0.07 Cr
4 Apr 2025	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	1,32,023	₹121.17	₹1.60 Cr
4 Apr 2025	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	1,32,023	₹121.03	₹1.60 Cr
4 Apr 2025	MUDUPULAVEMULA SURENDRANADHA REDDY	Bulk	NSE	Sell	1,23,412	₹121.51	₹1.50 Cr
4 Apr 2025	MUDUPULAVEMULA SURENDRANADHA REDDY	Bulk	NSE	Buy	1,23,412	₹120.96	₹1.49 Cr
4 Apr 2025	PARTH INFIN BROKERS PVT LTD	Bulk	NSE	Sell	1,10,803	₹124.36	₹1.38 Cr
4 Apr 2025	PARTH INFIN BROKERS PVT LTD	Bulk	NSE	Buy	1,10,803	₹125.31	₹1.39 Cr

1–10 of 41

1 / 5

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	6	13	9	22	32	23	329	21	31
	-8	-16	-10	0	11	18	0	-18	-21
	2	4	0	-32	1	0	35	0	-10
Net cash flow	0	1	-0	-10	45	41	364	3	1
Free cash flow	-2	9	4	22	32	23	329	21	14
CFO / Operating profit %	—	—	—	90.8%	136.5%	91.6%	—	70.2%	96.7%

Leverage
Current ratio	—	1.08	1.11	1.09	1.15	1.07	1.05

Bal Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

16

1

Announcements

16

1

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Working capital
Receivable days	—	98	98	113	107	111	110

Bal Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends16

Board meetings1

Announcements

Dividends16

Board meetings1

Not in the F&O segment

No fund holdings on record

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

16

1

16

1